ArticleFrontiers in immunology2026
Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombocytopenia is a frequent complication of human immunodeficiency virus (HIV) infection, tire arising through diverse mechanisms including autoimmune platelet destruction, advanced immunodeficiency, and systemic comorbidities. Distinguishing thrombocytopenia driven primarily by autoimmune platelet destruction from that related to advanced immunodeficiency remains a clinical challenge, as current standard markers often fail to stratify these distinct pathophysiological phenotypes. Methods: We conducted a case-control study enrolling 196 HIV-infected individuals (98 thrombocytopenia cases, 98 controls) to develop a clinical prediction model for HIV-associated thrombocytopenia. Candidate predictors were identified through univariable analysis, and AIC-based backward stepwise logistic regression was used to construct a parsimonious multivariable model. A nomogram was generated for bedside risk stratification, and dose-response analysis examined CD4+ T-cell counts and anti-platelet autoimmunity. Model performance was assessed through bootstrap resampling and 10-fold cross-validation, calibration by the Hosmer-Lemeshow test, and clinical utility by Decision Curve Analysis (DCA). Results: Anti-GPIIIa antibody positivity emerged as the dominant predictor of thrombocytopenia (aOR = 35.3; 95% CI: 9.2-135.6; Conclusions: This parsimonious model identifies an autoimmune-enriched phenotype of HIV-associated thrombocytopenia, characterized by anti-GPIIIa positivity and reduced immune and hematological reserves. Rather than confirming an immune-mediated etiology, the nomogram supports risk stratification to identify patients warranting further immunological evaluation. As treatment response was not prospectively evaluated and no independent reference standard was applied, external validation and prospective studies are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.